Search Results

Penumbra System Added to IMS III Stroke Trial Protocol

October 21, 2009—Penumbra, Inc. (Alameda, CA) announced that the Penumbra system has been added as a therapeutic option in the combined intravenous and intraarterial (IV/IA) therapy arm of the IMS III (International Management of Stroke III) trial, a prospective, randomized, controlled, international study of acute stroke intervention sponsored by the University of Cincinnati and the National Institute of Neurological Disorders and Stroke.

Penumbra System Added to IMS III Stroke Trial Protocol

October 21, 2009—Penumbra, Inc. (Alameda, CA) announced that the Penumbra system has been added as a therapeutic option in the combined intravenous and intra-arterial (IV/IA) therapy arm of the IMS III (International Management of Stroke III) trial, a prospective, randomized, controlled, international study of acute stroke intervention sponsored by the University of Cincinnati and the National Institute of Neurological Disorders and Stroke.

IMS 3 Stroke Study Shows Lack of Benefit for tPA Plus Endovascular Therapy Versus tPA Alone

February 7, 2013—The American Stroke Association (ASA) announced that results from the Interventional Stroke Management III trial (IMS 3) showed that adding endovascular therapy to clot-busting therapy for stroke did not significantly improve stroke recovery at 3 months.